HOME >> MEDICINE >> NEWS
Restrictive provincial drug policies may have benefits

The introduction of selective cyclooxygenase-2 inhibitors (COX-2 inhibitors, or coxibs), a group of nonsteroidal anti-inflammatory drugs (NSAIDs) widely used to treat arthritis and musculoskeletal problems, has resulted in a rapid increase in the number of people exposed to NSAIDs. Compared with traditional NSAIDS, coxibs are felt to offer a lower risk of stomach bleeding.

However, studies indicate that many patients who would otherwise not have used an NSAID are now using coxibs, with the net result of increased population rates of upper gastrointestinal (GI) bleeding. Mamdani and coauthors report on their comparison of changes over time in NSAID use and upper GI bleeding rates in British Columbia, which restricts the use of these drugs, and in Ontario, which has a less restrictive drug coverage policy. Their findings suggest that a more restrictive drug coverage policy, although limiting access to drugs and their potential benefits, may protect the population from adverse drug effects.


'"/>

Contact: Dr. G. Anderson
416-480-4780
Canadian Medical Association Journal
4-Dec-2006


Page: 1

Related medicine news :

1. Vicente Fox Center and RAND launch joint program to find policies to combat poverty
2. Smoking, growing private hospital care for poor and US flu vaccine policies
3. ACP challenges Congress to make fundamental changes in Medicare payment policies
4. Outdated policies are impediment for Americans with disabilities
5. A system in need of change -- restructuring payment policies to support patient-centered care
6. UCLA study reports conflict of interest policies and practices of major journals
7. Focus on opticians shows chain store pricing policies can save independents
8. Political party policies to reduce social inequalities have better health outcomes
9. Ireland leads Europe for anti-tobacco policies while Luxembourg comes last
10. Heart rhythm society issues draft recommendations on performance policies for pacemakers and ICDs
11. Resuscitation policies in long-term care settings should be reviewed

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/24/2017)... ... July 24, 2017 , ... ... management solution focused on delivering end-to-end sleep health care at scale, indicates ... literature shows that adherence rates for positive airway pressure (PAP) therapy, the most ...
(Date:7/24/2017)... BEACH, Calif. (PRWEB) , ... July 24, 2017 , ... ... ranging from food addiction to sexual abuse, and how she has overcome them. “Forbidden ... traumatic instances in her life and how she has risen above. , In “Memories,” ...
(Date:7/24/2017)... PA (PRWEB) , ... July 24, 2017 , ... ... 2030, today CURE announced that they have enrolled over 100,000 children in their ... afflicted children born every year in areas where treatment is limited or non-existent. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Clinical ... MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, VA, http://www.fdanews.com/cqa , ... Increased FDA scrutiny and growing demands to track and report adverse events place ...
(Date:7/24/2017)... ... July 24, 2017 , ... On July ... was set up, and the awarding ceremony was held successfully in Beijing. The ... of the army's health system, and national Chinese medicine experts also attended the ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/10/2017)... 2017 Locus Biosciences Inc. today announced the ... development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round ... Internet services provider, and joined by the North Carolina ... product programs targeting antibiotic resistant infections and other microbiome-related ... Dr. Rodolphe Barrangou and Dr. Charles ...
(Date:7/5/2017)... , July 5, 2017 Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... it has received approval from the Israel Securities Authority to ... (TASE). Oramed common stock will commence trading on the TASE ... the current market capitalization of the Company, it is expected ...
Breaking Medicine Technology:
Cached News: